Kodiak Sciences Inc.
$46.44
▼
-5.09%
2026-04-21 07:45:00
kodiak.com
NGM: KOD
Explore Kodiak Sciences Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.87 B
Current Price
$46.44
52W High / Low
$47.41 / $2.34
Stock P/E
—
Book Value
$2.55
Dividend Yield
—
ROCE
-76.6%
ROE
-1.49%
Face Value
—
EPS
$-4.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
124
Beta
2.4
Debt / Equity
37.6
Current Ratio
4.72
Quick Ratio
4.72
Forward P/E
-12.62
Price / Sales
—
Enterprise Value
$2.51 B
EV / EBITDA
-11.62
EV / Revenue
—
Rating
Strong Buy
Target Price
$56.33
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | KALA BIO, Inc. | $0.2 | — | $185.9 M | — | -88.86% | -388.29% | $20.6 / $0.15 | $-1.17 |
| 2. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 3. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 4. | InflaRx N.V. | $1.66 | — | $120.01 M | — | -114.26% | -88.63% | $1.94 / $0.71 | $0.67 |
| 5. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
| 6. | ImmunityBio, Inc. | $8.01 | — | $8.28 B | — | -58.17% | 71.02% | $12.43 / $1.83 | $-0.49 |
| 7. | Compass Therapeutics, Inc. | $5.42 | — | $1.08 B | — | -35.42% | -41.29% | $6.88 / $1.6 | $1.1 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -57.45 M | -62.35 M | -55.51 M | -59.07 M | -46.18 M | — |
| Net Profit | -56.74 M | -61.46 M | -54.31 M | -57.46 M | -44.1 M | — |
| EPS in Rs | -0.92 | -0.99 | -0.88 | -0.93 | -0.71 | -0.84 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -234.39 M | -186.85 M | -277.32 M | -341.38 M |
| Net Profit | -229.97 M | -176.21 M | -260.49 M | -333.82 M |
| EPS in Rs | -3.72 | -2.85 | -4.21 | -5.4 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 351.53 M | 335.58 M | 479.37 M | 666.63 M |
| Total Liabilities | 194.15 M | 185.29 M | 213.59 M | 230.46 M |
| Equity | 157.38 M | 150.29 M | 265.78 M | 436.17 M |
| Current Assets | 214.82 M | 171.94 M | 289.31 M | 486 M |
| Current Liabilities | 45.53 M | 25.57 M | 41.73 M | 52.5 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -136.01 M | -117.32 M | -154.18 M | -206.46 M |
| Investing CF | -0.51 M | -0.76 M | 249.23 M | -336.51 M |
| Financing CF | 178.3 M | 0.5 M | 0.03 M | 1.9 M |
| Free CF | -136.51 M | -117.72 M | -195.61 M | -253.82 M |
| Capex | -0.51 M | -0.4 M | -41.43 M | -47.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -30.51% | 32.36% | 21.97% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.